Angiodynamics Inc (ANGO) Stock Price, Quote & News

Company Profile

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy sy...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 518 795 1400

Website: www.angiodynamics.com

Address:

14 Plaza Drive, Latham, United States

SuperGreenToday Apr. 16 at 1:00 AM

$ANGO Share Price: $10.35 Contract Selected: Oct 16, 2026 $10 Calls Buy Zone: $1.32 – $1.63 Target Zone: $2.48 – $3.03 Potential Upside: 78% ROI Time to Expiration: 183 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Knot2 Apr. 15 at 2:06 PM

$ANGO something good is afoot

0 · Reply

SolarWind Apr. 7 at 3:34 PM

$ANGO created a substantial position today.

0 · Reply

PenkeInvesting Apr. 6 at 8:18 PM

Fundamental analysis of $ANGO (ANGIODYNAMICS INC) based on financial data and reported results. #ANGO #ANGIODYNAMICS

0 · Reply

JMJTrading Apr. 2 at 1:55 PM

$AYI over $300 this week, Earnings beat for 23 er in a row! $RGC $ANGO

0 · Reply

JMJTrading Apr. 2 at 12:53 PM

$AYI nice ER, lets see $300 break! $ANGO $LNN $VCX @DavidScott @topstockalerts

0 · Reply

StocktwitsEarnings Apr. 2 at 11:38 AM

$ANGO Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.19 down -72.73% YoY • Reported revenue of $78.42M up 8.91% YoY • AngioDynamics raised its full year FY 2026 guidance for net sales to $313.5M and Adjusted EBITDA to $10M. AngioDynamics expects Med Tech net sales growth of 15%-17% and anticipates slightly negative cash flow for FY26 due to inventory build.

0 · Reply

MorganHoratio Apr. 2 at 11:08 AM

BREAKING: AngioDynamics ($ANGO) just dropped its FQ3 FY2026 results — and the trend is loud and clear. DOUBLE-DIGIT growth in MedTech continues to power the engine Profitability sustained despite macro headwinds Momentum building in core segments while the company sharpens its focus on higher-margin innovation This isn’t just a quarterly beat — it’s a signal. Execution + growth + profitability = a setup traders can’t ignore. Watch for volume expansion and follow-through. When fundamentals align like this, moves can accelerate FAST. Is $ANGO setting up for the next leg higher… or just getting started?

0 · Reply

backtesttrend Apr. 2 at 10:24 AM

💉 $ANGO Reports Q3 FY2026 results Sustained double-digit growth in med tech Continues profitability trend

0 · Reply

Estimize Apr. 2 at 10:00 AM

$ANGO reported - EPS and - revenue for Q3. http://www.estimize.com/intro/ango?chart=historical&metric_name=eps&utm_content=ANGO&utm_medium=

0 · Reply

AngioDynamics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 2, 2026, 8:00 AM EDT - 23 days ago

AngioDynamics Earnings Call Transcript: Q3 2026

Apr 2, 2026, 6:00 AM EDT - 23 days ago

AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability

Mar 31, 2026, 8:00 AM EDT - 25 days ago

AngioDynamics to Present at the 25th Annual Needham Virtual Healthcare Conference

Mar 19, 2026, 8:00 AM EDT - 5 weeks ago

AngioDynamics to Report Fiscal 2026 Third Quarter Results on April 2, 2026

Mar 9, 2026, 1:40 PM EDT - 6 weeks ago

AngioDynamics Transcript: Leerink Global Healthcare Conference 2026

Feb 23, 2026, 4:30 PM EST - 2 months ago

AngioDynamics to Present at the Leerink Partners Global Healthcare Conference

Feb 19, 2026, 8:30 AM EST - 2 months ago

AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform

Feb 5, 2026, 8:00 AM EST - 2 months ago

AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care

Feb 3, 2026, 8:00 AM EST - 2 months ago

AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance

Jan 14, 2026, 6:00 PM EST - 3 months ago

AngioDynamics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 8:00 AM EST - 3 months ago

AngioDynamics Earnings Call Transcript: Q2 2026

Jan 6, 2026, 6:00 AM EST - 3 months ago

AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability

Dec 30, 2025, 6:51 AM EST - 4 months ago

AngioDynamics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Dec 23, 2025, 8:00 AM EST - 4 months ago

AngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026

Dec 22, 2025, 8:00 AM EST - 4 months ago

AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nov 10, 2025, 8:00 AM EST - 5 months ago

AngioDynamics Transcript: UBS Global Healthcare Conference 2025

Oct 27, 2025, 4:30 PM EDT - 6 months ago

AngioDynamics to Participate in the UBS Global Healthcare Conference

Oct 13, 2025, 8:30 AM EDT - 6 months ago

AngioDynamics' NanoKnife® System Named to TIME's 2025 Best Inventions List

Oct 2, 2025, 9:44 AM EDT - 7 months ago

Nasdaq Surges 100 Points; AngioDynamics Posts Upbeat Q1 Results

Oct 2, 2025, 8:00 AM EDT - 7 months ago

AngioDynamics Earnings Call Transcript: Q1 2026

Oct 2, 2025, 6:00 AM EDT - 7 months ago

AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum

Oct 1, 2025, 9:57 AM EDT - 7 months ago

Top Wall Street Forecasters Revamp AngioDynamics Expectations Ahead Of Q1 Earnings

Sep 18, 2025, 8:00 AM EDT - 7 months ago

AngioDynamics to Report Fiscal 2026 First Quarter Results on October 2, 2025

Aug 12, 2025, 9:00 AM EDT - 9 months ago

AngioDynamics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 6, 2025, 4:30 PM EDT - 9 months ago

AngioDynamics to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 28, 2025, 8:30 AM EDT - 9 months ago

AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia

Jul 23, 2025, 8:30 AM EDT - 9 months ago

AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology

Jul 15, 2025, 11:59 AM EDT - 10 months ago

AngioDynamics 'Exceptionally Well-Positioned' For 2026, CEO Says: But Tariffs Still Sting

Jul 15, 2025, 8:00 AM EDT - 10 months ago

AngioDynamics Earnings Call Transcript: Q4 2025

Jul 15, 2025, 6:30 AM EDT - 10 months ago

AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth

Jul 7, 2025, 8:00 AM EDT - 10 months ago

AngioDynamics to Report Fiscal 2025 Fourth Quarter and Full-Year Financial Results on Tuesday, July 15, 2025

Jun 23, 2025, 8:00 AM EDT - 10 months ago

AngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F1885 System for Treatment of Acute Pulmonary Embolism

Apr 2, 2025, 10:41 AM EDT - 1 year ago

Medical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Guidance

Apr 2, 2025, 9:00 AM EDT - 1 year ago

AngioDynamics Transcript: Investor Update

Apr 2, 2025, 8:00 AM EDT - 1 year ago

AngioDynamics Earnings Call Transcript: Q3 2025

Apr 2, 2025, 6:30 AM EDT - 1 year ago

AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results

Mar 31, 2025, 8:00 AM EDT - 1 year ago

AngioDynamics to Host Virtual Cardiovascular Investor Event

Mar 19, 2025, 8:00 AM EDT - 1 year ago

AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event

Mar 10, 2025, 4:30 PM EDT - 1 year ago

AngioDynamics to Present at the Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference

Jan 30, 2025, 7:30 AM EST - 1 year ago

AngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia

Jan 16, 2025, 10:30 AM EST - 1 year ago

AngioDynamics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 8:00 AM EST - 1 year ago

AngioDynamics Announces Publication of APEX-AV Trial Results in JSCAI

Jan 8, 2025, 9:30 AM EST - 1 year ago

AngioDynamics Transcript: Investor Update

Jan 8, 2025, 8:00 AM EST - 1 year ago

AngioDynamics Earnings Call Transcript: Q2 2025

Jan 8, 2025, 6:30 AM EST - 1 year ago

AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results

Jan 6, 2025, 9:26 AM EST - 1 year ago

AngioDynamics to Present at the J.P. Morgan Healthcare Conference

Jan 6, 2025, 9:25 AM EST - 1 year ago

AngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnife™ System

Dec 19, 2024, 5:00 PM EST - 1 year ago

AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event

Dec 9, 2024, 6:00 AM EST - 1 year ago

AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation

Oct 23, 2024, 8:00 AM EDT - 1 year ago

AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System

Oct 21, 2024, 8:00 AM EDT - 1 year ago

AngioDynamics Announces American Medical Association's CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver

Oct 3, 2024, 10:02 AM EDT - 1 year ago

AngioDynamics, Ingevity, Levi Strauss And Other Big Stocks Moving Lower On Thursday

LEVI NGVT

Oct 3, 2024, 8:00 AM EDT - 1 year ago

AngioDynamics Earnings Call Transcript: Q1 2025

Oct 3, 2024, 6:30 AM EDT - 1 year ago

AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results

Oct 3, 2024, 3:37 AM EDT - 1 year ago

Top Wall Street Forecasters Revamp AngioDynamics Price Expectations Ahead Of Q1 Earnings

Sep 19, 2024, 4:40 PM EDT - 1 year ago

AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes

Sep 19, 2024, 8:00 AM EDT - 1 year ago

AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024

Sep 3, 2024, 8:30 AM EDT - 1 year ago

AngioDynamics Announces CE Mark Approval in Europe for the Auryon System

Aug 13, 2024, 10:00 AM EDT - 1 year ago

AngioDynamics Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Jul 29, 2024, 4:15 PM EDT - 1 year ago

AngioDynamics to Participate in Upcoming Investor Conferences

Jul 16, 2024, 1:51 PM EDT - 1 year ago

Medical Devices Maker AngioDynamics Lays Out Growth Plans, Issues Upbeat Annual Guidance

Jul 16, 2024, 8:00 AM EDT - 1 year ago

AngioDynamics Earnings Call Transcript: Q4 2024

Jul 16, 2024, 6:30 AM EDT - 1 year ago

AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results

Jul 8, 2024, 4:30 PM EDT - 1 year ago

AngioDynamics to Report Fiscal 2024 Fourth Quarter and Full-Year Financial Results on July 16, 2024

May 21, 2024, 5:30 PM EDT - 2 years ago

AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System

May 6, 2024, 4:45 PM EDT - 2 years ago

AngioDynamics' APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions

Apr 4, 2024, 8:00 AM EDT - 2 years ago

AngioDynamics Earnings Call Transcript: Q3 2024

Mar 12, 2024, 12:40 PM EDT - 2 years ago

AngioDynamics Transcript: Oppenheimer 34th Annual Healthcare MedTech & Services Conference

Jan 11, 2024, 12:00 PM EST - 2 years ago

AngioDynamics Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 5, 2024, 8:00 AM EST - 2 years ago

AngioDynamics Earnings Call Transcript: Q2 2024

Oct 4, 2023, 8:00 AM EDT - 2 years ago

AngioDynamics Earnings Call Transcript: Q1 2024

Aug 9, 2023, 8:00 AM EDT - 2 years ago

AngioDynamics Transcript: Canaccord Genuity 43rd Annual Growth Conference

Jul 12, 2023, 8:00 AM EDT - 3 years ago

AngioDynamics Earnings Call Transcript: Q4 2023

Mar 30, 2023, 8:00 AM EDT - 3 years ago

AngioDynamics Earnings Call Transcript: Q3 2023

Jan 5, 2023, 8:00 AM EST - 3 years ago

AngioDynamics Earnings Call Transcript: Q2 2023

Oct 6, 2022, 8:00 AM EDT - 3 years ago

AngioDynamics Earnings Call Transcript: Q1 2023

Jul 11, 2022, 11:24 PM EDT - 4 years ago

AngioDynamics Earnings Call Transcript: Q4 2022

Apr 7, 2022, 1:14 PM EDT - 4 years ago

AngioDynamics Earnings Call Transcript: Q3 2022

Jan 5, 2022, 7:00 PM EST - 4 years ago

AngioDynamics Earnings Call Transcript: Q2 2022

Sep 29, 2021, 8:00 PM EDT - 4 years ago

AngioDynamics Earnings Call Transcript: Q1 2022

Jul 13, 2021, 10:48 AM EDT - 5 years ago

AngioDynamics Transcript: Investor Day 2021

Jul 13, 2021, 7:44 AM EDT - 5 years ago

AngioDynamics Earnings Call Transcript: Q4 2021

SuperGreenToday Apr. 16 at 1:00 AM

0 · Reply

Knot2 Apr. 15 at 2:06 PM

$ANGO something good is afoot

0 · Reply

SolarWind Apr. 7 at 3:34 PM

$ANGO created a substantial position today.

0 · Reply

PenkeInvesting Apr. 6 at 8:18 PM

Fundamental analysis of $ANGO (ANGIODYNAMICS INC) based on financial data and reported results. #ANGO #ANGIODYNAMICS

0 · Reply

JMJTrading Apr. 2 at 1:55 PM

$AYI over $300 this week, Earnings beat for 23 er in a row! $RGC $ANGO

0 · Reply

JMJTrading Apr. 2 at 12:53 PM

$AYI nice ER, lets see $300 break! $ANGO $LNN $VCX @DavidScott @topstockalerts

0 · Reply

StocktwitsEarnings Apr. 2 at 11:38 AM

0 · Reply

MorganHoratio Apr. 2 at 11:08 AM

0 · Reply

backtesttrend Apr. 2 at 10:24 AM

💉 $ANGO Reports Q3 FY2026 results Sustained double-digit growth in med tech Continues profitability trend

0 · Reply

Estimize Apr. 2 at 10:00 AM

$ANGO reported - EPS and - revenue for Q3. http://www.estimize.com/intro/ango?chart=historical&metric_name=eps&utm_content=ANGO&utm_medium=

0 · Reply

JMJTrading Apr. 1 at 9:47 PM

$AYI tomorrow morning is ER - Very bullish here - AYI has beaten earnings estimates for 22 consecutive quarters, 22, with an average surprise of 8% over the last year! Estimates: Consensus EPS is $4.11 on $1.09 billion in revenue, representing a 10.2% year-over-year earnings increase. Analyst have a "Moderate Buy" with an average price target of $380.17, that is 32% potential here. $ANGO $LNN $VCX

0 · Reply

isaac92173 Apr. 1 at 8:15 PM

$ANGO what is the news yall?

0 · Reply

SuperGreenToday Mar. 27 at 12:03 AM

$ANGO Share Price: $11.27 Contract Selected: Oct 16, 2026 $10 Calls Buy Zone: $1.70 – $2.10 Target Zone: $2.73 – $3.34 Potential Upside: 52% ROI Time to Expiration: 203 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

OfficialStocktwitsUser Mar. 25 at 3:46 AM

$ANGO RSI: 41.67, MACD: -0.1281 Vol: 0.33, MA20: 10.89, MA50: 10.74 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Estimize Mar. 23 at 1:21 PM

Wall St is expecting -0.11 EPS for $ANGO Q3 [Reporting 04/02 BMO] http://www.estimize.com/intro/ango?chart=historical&metric_name=eps&utm_c

0 · Reply

SwingPlay Mar. 18 at 6:51 PM

$ANGO breaking fucking $315 and we shall see $310 and $300 again.

0 · Reply

ZacksResearch Mar. 11 at 4:43 PM

Why $ANGO's growth story is just beginning! 🚀 With $ANGO's NanoKnife seeing revenue jump 22.2% YoY, driven by prostate cancer procedure adoption. Plus, the Auryon franchise reported its 18th straight quarter of double-digit growth in the second quarter. Discover why ANGO could continue to outperform 👉 https://www.zacks.com/stock/news/2882503/reasons-to-add-angiodynamics-stock-to-your-portfolio-for-now?cid=sm-stocktwits-2-2882503-body-37022&ADID=SYND_STOCKTWITS_TWEET_2_2882503_BODY_37022

0 · Reply

ZacksResearch Mar. 11 at 3:43 PM

$ANGO is gaining serious momentum — and the story might just be getting started. 👀 Strong fiscal Q2 results, surging NanoKnife adoption in prostate cancer, and broad Med Tech growth are all helping support margins and strengthen the investment case. See why ANGO could deserve a spot in your portfolio 👉 https://www.zacks.com/stock/news/2882503/reasons-to-add-angiodynamics-stock-to-your-portfolio-for-now?cid=sm-stocktwits-2-2882503-teaser-37012&ADID=SYND_STOCKTWITS_TWEET_2_2882503_TEASER_37012

0 · Reply

Estimize Mar. 11 at 10:03 AM

Wall St is expecting -0.11 EPS for $ANGO Q3 [Reporting 04/02 BMO] http://www.estimize.com/intro/ango?chart=historical&metric_name=eps&utm_c

0 · Reply

OfficialStocktwitsUser Mar. 4 at 12:51 PM

$ANGO RSI: 50.52, MACD: 0.0938 Vol: 0.38, MA20: 11.05, MA50: 11.26 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

ZacksResearch Feb. 23 at 6:14 PM

$ANGO just widened its oncology footprint in Europe — and that’s a big deal. AngioDynamics expanded NanoKnife’s EU indications to include liver, pancreas, kidney and prostate tumors, significantly broadening its reach and growth runway in multi-organ tumor ablation. That’s meaningful expansion, not incremental progress. Could this unlock the next leg of growth? Get the full breakdown 👉 https://www.zacks.com/stock/news/2873809/ango-expands-nanoknife-in-europe-for-multi-organ-tumor-ablation?cid=sm-stocktwits-2-2873809-teaser-34767&ADID=SYND_STOCKTWITS_TWEET_2_2873809_TEASER_34767

0 · Reply

ZacksResearch Feb. 23 at 5:14 PM

$ANGO gains on expanded NanoKnife approval in Europe! 🚀 Broader approvals for liver, pancreas, kidney, and prostate tumors open up significant market potential, reinforcing NanoKnife as a versatile oncology platform. 📈 With Europe contributing to 28% of global IRE volumes, ANGO is set for growth. Discover the full story here 👉 https://www.zacks.com/stock/news/2873809/ango-expands-nanoknife-in-europe-for-multi-organ-tumor-ablation?cid=sm-stocktwits-2-2873809-body-34751&ADID=SYND_STOCKTWITS_TWEET_2_2873809_BODY_34751

0 · Reply

Market Cap	462.77M
Revenue (ttm)	292.50M
Net Income (ttm)	-33.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-11.62%
Debt to Equity Ratio	0.00

Volume	237,600
Avg Vol	426,610
Day's Range	N/A - N/A
Shares Out	41.32M
Stochastic %K	83%
Beta	0.43
Analysts	Strong Sell
Price Target	$18.00